Biopharmaceutical company Opthea
(ASX:OPT) for eye disease has seen the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit.
This important milestone paves the way for the company to finalise data cleaning activities.
Patients enrolled in Opthea’s double-masked Phase 2b trial received intravitreal injections of OPT302 on a monthly basis for 6 months.
Of the 366 patients randomised in the trial, 348, that's 95.1 per cent of patients completed the week 24 visit.
Shares in Opthea
(ASX:OPT) closed -2.16 per cent lower at $0.68 yesterday.
